SC
GCVRZ

Savant Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Savant Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,993
Closed -$9K – 306
2018
Q3 		$9K Buy
+16,993
New +$9.11K ﹤0.01% 298

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NGA
New Generation Advisors Manchester, Massachusetts $45.6M AUM 15.43% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Savant Capital's GCVRZ Position: Q4 2018 in Review

Savant Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q4 2018, closing a stake of 16,993 shares — an estimated $9K sold.

Savant Capital first reported a position in GCVRZ in Q3 2018 and held it in 1 quarter. The position peaked at $9K in Q3 2018. 103 funds tracked by Wall St. Rank hold GCVRZ as of Q4 2018.

  • Savant Capital reported no remaining Sanofi Contingent Value Rights position as of Q4 2018 after selling out during the quarter.
  • Savant Capital sold 16,993 Sanofi Contingent Value Rights shares in Q4 2018, an estimated $9K.
  • Savant Capital first reported a position in Sanofi Contingent Value Rights in Q3 2018 and held it in 1 quarter.
  • Savant Capital's Sanofi Contingent Value Rights position peaked at $9K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q4 2018.

Based on Savant Capital's 13F filing for Q4 2018, filed 5 Feb 2019.